Nalaganje...

Systematic review of dasatinib in chronic myeloid leukemia

Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blast phase with resistance or intolerance to imatinib therapy, for newly diagnosed chronic phase patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Breccia, Massimo, Salaroli, Adriano, Molica, Matteo, Alimena, Giuliana
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2013
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3615898/
https://ncbi.nlm.nih.gov/pubmed/23569389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S35360
Oznake: Označite
Brez oznak, prvi označite!